Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders by Radu Constantinescu & Stefania Mondello
REVIEW ARTICLE
published: 21 January 2013
doi: 10.3389/fneur.2012.00187
Cerebrospinal fluid biomarker candidates for Parkinsonian
disorders
Radu Constantinescu1* and Stefania Mondello2
1 Department of Neurology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 Department of Anesthesiology, University of Florida, Gainesville, FL, USA
Edited by:
Jia-Yi Li, Lund University, Sweden
Reviewed by:
Davide Martino, Queen Mary
University of London, UK
Edina Silajdzic, Lund University,
Sweden
*Correspondence:
Radu Constantinescu, Department of
Neurology, Institute of Neuroscience
and Physiology, The Sahlgrenska




The Parkinsonian disorders are a large group of neurodegenerative diseases including idio-
pathic Parkinson’s disease (PD) and atypical Parkinsonian disorders (APD), such as multiple
system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia
with Lewy bodies. The etiology of these disorders is not known although it is considered
to be a combination of genetic and environmental factors. One of the greatest obstacles
for developing efficacious disease-modifying treatment strategies is the lack of biomark-
ers. Reliable biomarkers are needed for early and accurate diagnosis, to measure disease
progression, and response to therapy. In this review several of the most promising cere-
brospinal biomarker candidates are discussed. Alpha-synuclein seems to be intimately
involved in the pathogenesis of synucleinopathies and its levels can be measured in the
cerebrospinal fluid and in plasma. In a similar way, tau protein accumulation seems to
be involved in the pathogenesis of tauopathies. Urate, a potent antioxidant, seems to be
associated to the risk of developing PD and with its progression. Neurofilament light chain
levels are increased in APD compared with PD and healthy controls. The new “omics”
techniques are potent tools offering new insights in the patho-etiology of these disorders.
Some of the difficulties encountered in developing biomarkers are discussed together with
future perspectives.
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PARKINSONIAN DISORDERS
The Parkinsonian disorders have in common, to various degrees,
the parkinsonism, defined as the presence of at least two of six
movement abnormalities, of which either no. 1 or no. 2 are com-
pulsory: (1) hypokinesia or diminished movement activity (also
called bradykinesia, slowness of movement); (2) rest tremor; (3)
rigidity (muscular stiffness); (4) loss of postural reflexes; (5) flexed
posture; and (6) the freezing phenomenon (when the feet seem
temporarily to be glued to the floor; Fahn, 2003). In addition
to the motor abnormalities, specific combinations of non-motor
symptoms such as autonomic and neuropsychiatric disorders, bal-
ance and ocular movement abnormalities, developing at various
disease stages, characterize each particular Parkinsonian disorder,
with major implications with regard to morbidity, treatment, and
prognosis.
The Parkinsonian disorders (Figure 1) represent a large group
of neurodegenerative diseases affecting a considerable number of
patients, most of whom are elderly. Parkinson’s disease (PD) dom-
inates the group by far, as the most prevalent in the population, but
also on scientific grounds, as a flagship for neurodegeneration in
general, and due to the overwhelming impact which levodopa, its
highly efficacious symptomatic treatment, has had on neurology.
To the more uncommon atypical Parkinsonian disorders (APD)
belong multiple system atrophy (MSA), progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD), and dementia with
Lewy bodies (DLB). Depending on the nature of the abnormal
proteins which aggregate in the nervous tissue in these diseases,
they can be subclassified as either synucleinopathies (PD, MSA,
and DLB) with alpha-synuclein accumulation, or tauopathies
(PSP and CBD) with tau protein accumulation. The oftentimes
deceptively similar clinical pictures of these diseases can make the
differential diagnosis difficult, especially in early stages; generally,
the clinical diagnostic accuracy is lower for APD compared with
PD (Hughes et al., 2002). Due to the global aging of the popula-
tion, the number of patients affected by these, for now, incurable
disorders will expand in the future (Dorsey et al., 2007), with con-
siderable strains on the health care system and society at large,
increasing the need for developing new, efficacious therapies.
BIOMARKERS
DEFINITION
The word “biomarker” is being used widely but not always cor-
rectly. The term was defined in 2001 by the Biomarkers Definitions
Working Group as “A characteristic that is objectively measured
and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeu-
tic intervention” (Biomarkers Definitions Working Group, 2001).
Surrogate endpoints are a subgroup of biomarkers. They are a sub-
stitute for clinical endpoints which is what we really are interested
in, reflecting how the patient is doing in reality. The require-
ments for a biomarker to serve as a surrogate endpoint are very
strict and, at the present time, we do not have any surrogate
endpoints in Parkinsonian disorders. However, any reliable bio-
marker, even if not strong enough to be a surrogate endpoint,
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FIGURE 1 | Simplified and non-exhaustive visual representation of
two groups of protein accumulation disorders (synucleinopathies and
tauopathies), two major groups of symptoms (Parkinsonism and
cognitive impairment), and some but not all possible interactions
in-between. All of the depicted disorders are Parkinsonian disorders with
the exception of Alzheimer’s disease. The figure is not on scale. AD,
Alzheimer’s disease; CBD, corticobasal degeneration; DLB, dementia with
Lewy bodies; MSA, multiple system atrophy; PD, Parkinson’s disease; PSP,
progressive supranuclear palsy. Dashed line, atypical Parkinsonian
disorders.
would be tremendously valuable. In order for a parameter to
be considered a biomarker for a certain disease, it must fulfill
several requirements: (1) Validity: there must be a correlation
between the biomarker and the disease which it stands for; a
treatment must affect the disease and not only the biomarker
itself; (2) Performance: how good is the biomarker? How well
does it differentiate between affected and non-effected? The bio-
marker assessment must be reliable and reproducible, both in the
same patient at different points in time, and at different cen-
ters. It must be feasible in a clinical context and that implies
safety, tolerability, simplicity, and low cost; (3) Generalizability:
the performance in different patient subsets, based, e.g., on age,
gender, disease stage, and medication, must be known (Brooks
et al., 2003; Marek et al., 2008). It is easy to use the word “bio-
marker,” but the implications of this word are profound, and
despite all the efforts, we cannot say, for the time being, that
we really have a biomarker for Parkinsonian disorders. What
we do have in neurological sciences are: (1) biomarkers for cer-
tain disease-related processes, such as neurofilament light chain
(NFL) as a biomarker of axonal degeneration, particularly dam-
age to large-caliber, myelinated axons; and (2) different forms of
protein inclusions, such as the 42 amino acid isoform of amy-
loid β (Aβ42) as a biomarker of Alzheimer-related senile plaque
pathology.
TYPES OF POTENTIAL BIOMARKERS FOR PARKINSONIAN DISORDERS
There are different types of potential biomarkers for neurode-
generative disorders: biochemical analysis of blood, cerebrospinal
fluid (CSF), urine or brain tissues, genetics, and multiple imaging
modalities (e.g., different MRI techniques, SPECT, PET, and ultra-
sound of substantia nigra). In addition, several clinical markers are
used to measure different aspects of the diseases and to track their
progression: motor analysis; assessments of olfaction, autonomic
functions, cognition, sleep, speech and swallowing, neuropsycho-
logical, and psychiatric investigations (Marek et al., 2008). This
overview is only concerned with biochemical markers, mostly in
the CSF but to a lesser degree also in the blood.
According to the aims of the investigation and the technique
utilized, there are two main approaches to assess body fluids and
body/brain tissues for biomarkers:
(1) Targeted search to investigate one or several a priori defined
compounds in patients and in healthy controls and looking
for differences, patterns, and associations.
(2) Untargeted search to investigate broadly a large amount of
components in a sample and compare patients with healthy
controls. Nowadays, this is achieved by the“omics”techniques.
THE “OMICS” TECHNIQUES
The relatively new “omics” techniques present both an enormous
potential, through their capacity of screening wide and comple-
mentary areas of different biological materials, and a significant
challenge, through the huge amount of data that are generated
and need interpretation. In biologic materials, transcriptomics,
proteomics, and metabolomics evaluate the transient, momenta-
neous, or “state” characteristics of a sample while genomics mirror
its permanent or “trait” characteristics.
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GENOMICS
Genomic studies survey and compare genomes in patients and
controls, looking for associations between gene alleles, genetic risk
factors, and disease. The more restricted candidate gene approach
investigates specific genes in the context of a certain disease, such as
mutations in the alpha-synuclein gene (SNCA) causing a rare form
of autosomal dominant PD. The genome-wide association studies,
a more recent technique, investigate the whole genome. Genetic
studies and metaanalyses have found more than 16 PARK loci
associated with PD and 11 genes for PARK loci, and new insights
are gained every year (International Parkinson’s Disease Genomics
Consortium and Wellcome Trust Case Control Consortium, 2011;
Lill et al., 2012). Five of the identified genes induce a roughly
typical PD presentation [a-synuclein, parkin, PTEN induced puta-
tive kinase 1, DJ-1, and leucine-rich repeat kinase 2 (LRRK2)]
while mutations of ATP13A2 (PARK9) cause Kufor–Rakeb disease
characterized by both Parkinsonism and many atypical features
(Coppede, 2012). A genetic biomarker is unchangeable and indi-
cates a trait, a predisposition to develop a disease. However, it does
not indicate whether the disease has started or how advanced it is;
it does not provide information about the state. Due to environ-
mental factors, age, or reduced penetrance, the trait may or may
not induce a state of disease during the lifetime of the bearer. The
LRRK2 mutation is an example of a genetic trait for an autoso-
mal dominant form of PD with variable penetrance probably due
to non-genetic factors. Through genome-wide association stud-
ies, Simon-Sanchez et al. (2009) found a strong association in
PD with the alpha-synuclein gene (SNCA) and, surprisingly for a
synucleinopathy, also with the MAPT locus, related to tau protein.
An emerging research field is epigenetics which may bridge
the gap between the apparently unchanging genome and the ever
changing environment. There is evidence from both human but
mostly from in vitro and animal models that DNA methylation,
histone modifications, and small RNA-mediated mechanisms,
could modify the expression of PD-related genes such as the
alpha-synuclein gene, DJ-1, LRRK2, and parkin-gene, and thereby
contributing to the development of the disease (Marques et al.,
2011; Coppede, 2012).
TRANSCRIPTOMICS
Transcriptomics investigates mRNA levels of expressed genes cod-
ing for proteins. Several studies have examined cells from sub-
stantia nigra in PD patients, controls, and PD animal models.
Differences were found between controls and patients but the
results in regard to particular genes were not similar between
studies (Smith, 2009; Caudle et al., 2010). However, looking at
patterns, findings became more consistent across studies and a pat-
tern could be discerned showing that genes involved in oxidative
stress, mitochondrial function, protein degradation, dopaminer-
gic transmission, and axonal guiding were expressed differently in
the different diagnostic groups (Smith, 2009; Caudle et al., 2010).
PROTEOMICS
Proteomics characterizes the protein content – the proteome of a
sample. Comparing the proteomes of patients and controls, differ-
ences may be found. The technology is based on three components:
(1) separation of proteins; (2) analyzing proteins through mass
spectrometry; and (3) quantifying and identifying the proteins
through advanced data processing (Caudle et al., 2010). Using this
technique, a comprehensive characterization of the proteome in
substantia nigra was made by one group (Kitsou et al., 2008).
Many of the proteins known to be involved in PD such as DJ-1
and UCHL-1 were identified. Using proteomics, the proteome of
the CSF was characterized and over 1500 proteins were identified
and grouped according to their functions, such as cell cycle, signal
transduction, and cellular transport. In addition, a large number
of proteins unique to PD, AD, and DLB were identified (Abdi et al.,
2006). Seventy two of them were uniquely altered in PD compared
with healthy controls. Apolipoprotein H (Apo H) and ceruloplas-
min appeared to be able to segregate PD from healthy controls and
from non-PD (AD and DLB). Using the same material, Zhang et al.
(2008) validated a multianalyte CSF profile, identifying a panel of
eight CSF proteins that were highly effective at recognizing PD. In
a study in PD, MSA, CBD, PSP, and healthy controls, a panel of
four proteins (ubiquitin, β2-microglobulin, and 2 secretogranin
1 [chromogranin B] fragments) was identified which could dif-
ferentiate PD and healthy controls on one side from APD on the
other side with an AUC of 0.8 (Constantinescu et al., 2010a).
Subcellular proteomics investigates the proteome at the sub-
cellular level, in compartments of the cell. Such a compartment
is neuromelanin, a granular pigment associated with lysosomes
and present in cathecolaminergic neurons. It interacts with com-
pounds in the cytoplasm such as iron, lipids, pesticides, neurotox-
ins, and it sequesters them, thus having a cytoprotective function.
However, if it malfunctions, it could turn out to become cytotoxic
and be involved in neurodegeneration. The proteins associated
with neuromelanin were investigated using proteomics (Tribl et al.,
2006). Several were associated with mitochondrial function and
chaperons. Interestingly, antibodies against neuromelanin have
been found in serum from PD patients (Double et al., 2009).
Subcellular proteomics was also used for analyzing Lewy bodies.
Several proteins thought to be involved in the pathogenesis of PD
were found, associated with alpha-synuclein, such as chaperons,
proteins involved in oxidative stress, and proteosomal degradation
(Xia et al., 2008). Analyzing mitochondrial fractions, 119 proteins
were found to differ in PD compared with controls. Especially
interesting is mortalin, involved in mitochondrial function and
oxidative stress reactions. Low levels of mortalin were found in
substantia nigra from PD patients compared with controls (Jin
et al., 2006).
A shortcoming of the proteomics technique is that it is often
biased toward identification of abundant proteins. As albumin and
immunoglobulins represent more than 70% of CSF proteins, a way
to enhance the discovery of proteins present in small amounts is
to exclude the abundant proteins from the sample through frac-
tionation. Blood contamination with its high protein content can
dramatically alter CSF proteomic pattern and it has been suggested
to exclude from proteomic analyses CSF containing more than 10
erythrocytes per microliter (Caudle et al., 2010).
METABOLOMICS
Metabolomics investigates end products of metabolic pathways.
These are molecules with low molecular weights required for the
maintenance, growth, and normal function of a cell (Beecher,
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2003). Adequate sample collection and preparation prior to analy-
sis is very important for accurate results. Metabolomic studies con-
ducted by Bogdanov et al. have confirmed the inverse association
between blood urate levels and the risk for PD. In addition, they
found higher levels of glutathione and 8-hydroxydeoxyguanosine
(8-OHdG) in PD compared with controls. These compounds are
markers of oxidative processes and support the oxidative stress
hypothesis in PD (Bogdanov et al., 2008). The same group could
differentiate controls from idiopathic PD patients, patients with
idiopathic PD from those with hereditary PD caused by the
G2019S variant of the LRRK2 mutation, and also symptomatic
LRRK2 mutation carriers from asymptomatic carriers, based on
the metabolomic profile (Johansen et al., 2009).
CONCLUSION
Ideally, findings from the four “omics” techniques applied on dif-
ferent materials (e.g., substantia nigra cells or the CSF) should
be consistent. Thus, if genomics shows an altered gene in neu-
ronal nuclei, then the mRNA (transcriptomics) should reflect that
in the cytoplasm, and further, after translation, in proteins and
through them metabolic products detected in the cell or in the
CSF by proteomics and ultimately by metabolomics. Findings in
the CSF should be replicated in substantia nigra cells. Unfortu-
nately, this congruence of findings is not often to be seen. That
may be due to the limitations of the techniques or experimental
incongruences, along with the use of different techniques and the
inherent complexities of living organisms (Caudle et al., 2010).
Better equivalence is achieved when findings from different tech-
niques are categorized within pathways such as oxidation, synaptic
transmission, mitochondrial function, or protein degradation. Of
these, the oxidative stress pathway is the most robust with similar
results from both cellular and CSF analysis, from genomics, tran-
scriptomics, proteomics, and metabolomics. Thus, oxidative stress
appears to be the final common pathway in the neurodegenera-
tive process in PD (Caudle et al., 2010). Better integration of these
techniques should lead to a deeper understanding of the patho-
physiology of PD as well as other neurodegenerative disorders, and
open venues for developing new treatment strategies.
CEREBROSPINAL FLUID
The first lumbar puncture (LP) was done in London 1889 and
CSF studies have a long tradition in neurology, both in research
and in clinical practice (Frederiks and Koehler, 1997). We know
mainly from AD research that CSF studies in patients with neu-
rodegenerative disorders are feasible with a low rate of post LP
headache or other complications (Andreasen et al., 2001) and
CSF analysis for assessing tau protein and beta-amyloid belongs
now to the standard of care in the management of dementias.
Brain-derived proteins do not usually appear in the blood due
to the blood-brain barrier. In contrast, CSF is very close to the
pathologic processes in the brain, and may better reflect changes
in brain metabolism (Mollenhauer and Zhang, 2012). This may
offer advantages when investigating neurodegenerative disorders.
Even though protected by the blood-brain barrier, the CSF is
dynamic. Proteins that diffuse in the CSF from plasma have a
concentration gradient with a 2.5 times higher lumbar concen-
tration than cranial. Proteins secreted in the CSF from the brain
have about the same concentration in the CSF space, but some,
including tau protein, may actually have a lower concentration
distally, in the lumbar region. There are also diurnal variations,
as the secretion of proteins into the CSF is higher at night. In
addition, the protein concentration decreases between the first ml
CSF tapped at the LP and the later portion which is the preferred
one as it more accurately reflects the environment in the brain.
All this makes imperative the standardization of the CSF sampling
protocol (Kroksveen et al., 2011).
It has been suggested that CSF itself mediates humoral signaling
which is distinct from synaptic neurotransmission. In one study,
spherical nanometric-scale structures were identified in the CSF
containing synaptic vesicles (Harrington et al., 2009). Cell-line
studies have shown that CSF from PD patients affects dopamin-
ergic cells differently than CSF from healthy controls, implying
that there are differences in their composition (Le et al., 1999).
Due to all this, CSF has been widely investigated in Parkinsonian
disorders and it might be considered to offer the most promising
insights in the disease processes (Lewitt, 2012).
There have been concerns regarding CSF sample handling and
its impact on the acuity of CSF data as post-translational modifica-
tions, protein loss, and degradation can be caused by non-optimal
CSF related procedures including sampling, freezing, thawing, and
storage. Therefore it is important to have standard operating pro-
cedures in place (Lewczuk et al., 2006). A consensus protocol for
the standardization of CSF collection and handling has been pub-
lished in 2009 and is being followed by many European centers
(Teunissen et al., 2009). In regard to analysis, for increasing the
reliability of results, a study should ideally include a training sub-
group and a validation subgroup, the latter preferably run by a
different research group (Zetterberg et al., 2008; Mollenhauer and
Trenkwalder, 2009).
CSF BIOMARKER CANDIDATES FOR PARKINSONIAN
DISORDERS
In a review by Mollenhauer et al. from 2008 of all then current
publications regarding CSF biomarkers in PD, MSA, PSP, CBD,
and DLB, no less than 67 tested compounds were identified, most
of them in PD. However, several limitations were found in most
of the studies: sensitivity and specificity were low; there was a
lack of reproducibility of results by independent cohorts; and the
analysis methods in use were still considered to be in their infancy
(Mollenhauer and Trenkwalder, 2009). Thus, there is no scarcity
of investigations on CSF compounds with biomarker potential
in Parkinsonian disorders. What we barely have are mature CSF
biomarker candidates and what we still lack is a real biomarker.
Historically, due to the prominence of the dopaminergic abnor-
malities in these disorders, the first compounds to be tested
were dopamine and other monoamines and their metabolites.
As these results were prone to be influenced by a multitude of
other factors, the quest went further to compounds which were
already known and tested in other diseases such as tau protein,
beta-amyloid, and NFL. With advancing knowledge and technical
capabilities, the search turned further toward specific targets fol-
lowing theoretical considerations in regard to patho-etiology, such
as alpha-synuclein, or inflammatory markers. Later on, the newer
and far-reaching possibilities offered by the “omics” techniques
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led to broad searches surveying large, nod-discriminate entities
like the genome or the proteome. The overview presented here has
no claim on being exhaustive; instead it focuses on a number of
compounds perceived to be more mature and/or promising for
the future.
SPECIFIC BIOMARKER CANDIDATES IN THE CSF AND BLOOD
A summary is presented in Table 1.
Alpha-synuclein
Background. Alpha-synuclein is the main component of intra-
cytoplasmatic Lewy bodies and of Lewy neurites in neuronal
processes. These structures are found in PD and in DLB in the
remaining dopaminergic neurons in substantia nigra, and also in
non-dopaminergic cortical and non-cortical neurons (Jellinger,
1990, 2003). In MSA, alpha-synuclein is a component of the
characteristic glial intracytoplasmatic inclusions.
Mutations affecting the gene coding for alpha-synuclein cause
rare hereditary forms of PD, such as in PARK1 (missense) and
PARK4 (duplication, triplication; Polymeropoulos et al., 1997) but
are also important for sporadic forms of PD (Farrer et al., 2001). In
addition, in both PD and MSA, genome-wide association studies
showed a strong association between disease risk and distinct sin-
gle nucleotide polymorphisms (SNPs) in theα-synuclein encoding
gene (Simon-Sanchez et al., 2009). There seems to be a dose-effect
of alpha-synuclein as increased levels of synuclein caused by dupli-
cations and triplications of the gene cause PD (Fuchs et al., 2008;
Simon-Sanchez et al., 2009).
Alpha-synuclein’s role in the pathogenesis of synucleinopathies.
Although it is widely expressed in the brain, the precise func-
tion of alpha-synuclein is not known. It might play an important
role in neurotransmission by regulating synaptic vesicle size and
recycling. Mutant alpha-synuclein builds fibrils, aggregates, resists
degradation, and ultimately interferes with vital cell functions such
as transcription, the ubiquitin-proteasome system, lysosomes and
mitochondria,disrupting protein metabolism,and energy produc-
tion. Oxidation, pesticides, and mitochondrial dysfunction can
damage alpha-synuclein and initiate its metamorphosis to toxic
forms (Moore et al., 2005). It has been proposed that alpha-
synuclein pathology and subsequent neurodegeneration could
represent a common event for different forms of PD, with different
etiologies. A recent theory proposes pathologic“seeding”through-
out the nervous system of abnormal alpha-synuclein which, after
finding its way in the body, might, through a prion-like induction,
spread from cell to cell, causing the neurodegenerative process in
PD (Angot et al., 2010; Jucker and Walker, 2011). Due to alpha-
synuclein’s prominence in the pathogenesis of these disorders, PD,
MSA, and DLB are considered to be synucleinopathies.
Previous findings in Parkinsonism. Cerebrospinal fluid alpha-
synuclein levels in PD have been investigated using different tech-
niques in over 10 studies. A majority of them showed decreased
levels in PD (Tokuda et al., 2006; Mollenhauer et al., 2008; Hong
et al., 2010; Mollenhauer et al., 2011) but not all (Borghi et al.,
2000; Ohrfelt et al., 2009).
Four studies have investigated CSF alpha-synuclein levels in
MSA. Three of them found decreased levels in MSA compared
with controls but not with PD patients (Mollenhauer et al., 2011;
Shi et al., 2011; Hall et al., 2012). In one of them levels were similar
in MSA, PD, and controls (Tateno et al., 2012). In one study, PD
and MSA could be differentiated by the CSF Flt3 ligand, not by
alpha-synuclein (Shi et al., 2011).
In one study, CSF alpha-synuclein levels in PSP and CBD were
not significantly different compared with controls. However, levels
in PSP but not in CBD were higher than in PD (Hall et al., 2012).
Alpha-synuclein levels have also been investigated in plasma
in PD and MSA but with conflicting results. Both higher (Lee
et al., 2006) and similar (Li et al., 2002) levels compared with
controls have been found and there was no correlation with PD
severity. A major difficulty in measuring both alpha-synuclein and
DJ-1 in plasma is the risk for contamination with erythrocytes or
platelets as more than 95% of these compounds reside in erythro-
cytes and about 4% in platelets. However, even after controlling
for that, there were no statistically significant differences between
PD patients and controls in regard to these compounds although
there was a trend for lower levels in PD. It does not seem that
plasma alpha-synuclein can be used as a biomarker for PD for the
time being (Shi et al., 2010).
Oligomeric forms of alpha-synuclein protein in plasma were
higher in PD than in controls, in one study (El-Agnaf et al., 2006).
However, in another study, phosphorylated alpha-synuclein, but
Table 1 | Cerebrospinal fluid biomarker candidates in Parkinsonian disorders.
Compound PD MSA PSP CBD Conclusion
Alpha-synuclein ↓ ↔ ↓ ↔ ↔ ↑ ↔ Decreased in PD and MSA but not in PSP and CBD. Inconsistent data
NFL ↔ ↑ ↑ ↑ NFL normal in PD but increased in MSA, PSP, and CBD, vs. controls
Total tau protein ↓ (↑)↔ ↑ ↓ ↔ ↔ ↑ ↔ Decreased in PD and increased in CBD. Inconsistent data
Aβ42 ↓ ↔ ↓ ↔ ↓ ↔ ↓ ↔ Decreased in PDD and DLB. Inconsistent data in PD, MSA, PSP, and CBD
DJ-1 ↑ ↓ – – – Data is not consistent
8-OHdG ↑ – – – Limited results. Probably increased in PD
Urate [↓] [↓] – Lower urate levels are associated with a higher risk for developing PD and
with a faster rate of disease progression in PD and MSA
Aβ42, amyloid-β; CBD, corticobasal degeneration; DLB, dementia with Lewy bodies; MSA, multiple system atrophy; NFL, neurofilament light chain; PD, Parkinson’s
disease; PDD, Parkinson’s disease with dementia, PSP, progressive supranuclear palsy; vs., versus. 8-OHdG, 8-hydroxydeoxyguanosine.
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not total alpha-synuclein nor oligomers of alpha-synuclein, was
higher in PD than in controls (Foulds et al., 2011). Interest-
ingly, antibodies directed against monomeric alpha-synuclein
were found in plasma of PD patients, with higher response in ear-
lier disease phases (Yanamandra et al., 2011). Studies in animal
models suggest that immunomodulatory interventions such as
vaccination with alpha-synuclein (Masliah et al., 2005) or admin-
istration of alpha-synuclein antibodies (Masliah et al., 2011) may
have a positive impact on the intraneuronal accumulation of
alpha-synuclein, presumably reflected by reduced neuropatholog-
ical and behavioral deficits. Intravenous immunoglobulin reduced
alpha-synuclein oligomer neurotoxicity in human neuroblastoma
cells (Smith et al., 2012). These results may motivate further
research aiming to find whether immunomodulation might be
a novel therapeutic approach in PD.
Alpha-synuclein was found not only in the brain and the blood
but in other peripheral locations too. It was found in the colonic
mucosa years before the emergence of PD symptoms and the ques-
tion was raised whether it can be a biomarker for premotor PD
stages (Shannon et al., 2012a,b). In saliva, alpha-synuclein was
lower in PD patients than in controls and it inversely correlated
with the UPDRS score (Devic et al., 2011).
Cerebrospinal fluid alpha-synuclein levels increase non-
specifically in Creutzfeldt–Jakob’s disease, presumably due to mas-
sive neuronal death (Mollenhauer et al., 2008). The same phe-
nomenon but on a smaller scale occurs in AD, with increased CSF
alpha-synuclein levels (Hall et al., 2012).
Although alpha-synuclein is a strong biomarker candidate due
to its important role in the pathogenesis of synucleinopathies and
to several promising results, currently it cannot be considered a
mature biomarker. However, in a group of parkinsonian patients,
low CSF alpha-synuclein levels could help with their stratification,
due to its high positive predictive value for synucleinopathies. An
additional marker (e.g., non-motor prodromal symptoms) would
strengthen the stratification process and help to select a group of
patients who may benefit from future synuclein-reducing thera-
pies (Mollenhauer et al., 2011). Longitudinal studies and studies
in early disease stages are needed in order to better understand the
value of alpha-synuclein as potential biomarker in Parkinsonism.
Neurofilament light chain protein
Background. Neurofilaments (NF) are major neuronal structural
elements, composing the intermediate filaments present in nerve
fibers. They are mainly involved in maintaining the axonal cal-
iber and the neuronal shape and size (Lasec, 1988) and are thereby
critical for the morphological integrity of neurons and for the con-
duction of nerve impulses along the axons (Hoffman et al., 1987).
The NF are composed of three subunits of different molecular
weights: light chain NF (NFL), medium chain NF (NFM), and
heavy chain NF (NFH). The NFL forms the backbone to which
NFH and NFM chains copolymerize to form NF. Increased levels
of CSF NF primarily reflect axonal degeneration of large myeli-
nated axons, such as those present in the pyramidal tracts. NFL is
a mainly non-phosphorylated protein, whereas NFH is substan-
tiality phosphorylated (pNFH), and can be measured in that form.
CSF NFL has been shown to be increased in a variety of acute and
chronic neurological diseases (Rosengren et al., 1996; Rosengren
et al., 1999; Zetterberg et al., 2006; for review, see Norgren et al.,
2003).
Previous findings in Parkinsonism. NFL has been investigated
in Parkinsonian disorders in a relatively large number of stud-
ies (Holmberg et al., 1998; Holmberg et al., 2001; Abdo et al.,
2007a; Abdo et al., 2007b). A review from 2009 concluded that
NFL could differentiate between PD and controls on one side and
MSA and PSP on the other side, although with overlap. NFL could
not discriminate between MSA with predominant Parkinsonism
and MSA with predominantly cerebellar symptoms, nor between
MSA and PSP (Constantinescu et al., 2009). Consecutive analy-
ses of CSF NFL did not show any significant changes over 1 year
and no correlation with disease severity. CSF NFL levels were also
increased in CBD (Constantinescu et al., 2010b). Several studies
have been conducted since then with similar findings (see Combi-
nations of CSF Compounds for the most recent results). Hall et al.
(2012) found increased NFL in MSA, PSP, and CBD. In one study
in advanced PD patients treated with deep brain stimulation of
nucleus subthalamicus, CSF NFL levels increased sharply directly
after surgery but normalized gradually and were normal at 1 year
and later. Thus, using this method, no signs of accelerated neuronal
death due to active DBS could be found (Constantinescu et al.,
2011). To be able to ascertain that a therapy is not in itself delete-
rious for the disease being treated remains a key point, and even
more as new therapeutic approaches to PD are envisioned that
employ potentially harmful techniques (e.g., intracranial catheters
for injection of neurotrophic factors, cell transplants, and genet-
ical modifications using viral vectors). Thus, in the future there
may arise the need to detect adverse events using a sensitive, albeit
non-specific, marker for brain damage. In this context, CSF NFL
with its high sensitivity for detecting more aggressive neuronal
death than it occurs in PD, even if enfeebled by a low diagnostic
specificity, might be of use.
Tau protein
Background. Tau protein is important for the function of axonal
microtubules and thereby for the structural integrity of the neu-
ron and for axonal transport. In hyperphosphorylated form it
has reduced binding affinity for microtubules and leads to their
malfunction. At the same time, it adopts an abnormal configura-
tion favoring aggregation and inclusion formation (Kouri et al.,
2011). Tau protein is the main structural element of neurofibrils
in Alzheimer’s disease (AD) but it has also been found in neurofib-
rillary tangles in PSP, in neuronal cytoplasmatic inclusions, and in
ballooned neurons in CBD and PSP (Mori et al., 1994).
Previous findings in Parkinsonism. Cerebrospinal fluid tau pro-
tein levels in Parkinsonism have been investigated in many studies
in the past, with inconclusive results. In PD, most studies found
normal values, but both higher and lower values were reported. In
atypical Parkinsonism, tau levels tended to be higher in MSA than
in PD, but not in PSP. The results for CBD are mixed, with both
higher and lower levels than in controls being reported (for review
of older literature, see Constantinescu et al., 2009).
Recently, in a large study on patients with dementia, total tau
and phosphorylated tau levels were not significantly different in
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PSP and CBD compared with controls (patients with subjective
memory complaints; Schoonenboom et al., 2012). In four recent
large studies, tau protein was investigated along with other CSF
compounds (see Combinations of CSF Compounds).
Amyloid-β
Background. Aβ42, derived from the proteolytic processing of a
larger protein, amyloid precursor protein, is a major component
of neuritic plaques in AD. Due to its sequestration in plaques, the
characteristic pattern in AD is low CSF Aβ42 levels. Low CSF con-
centrations have also been found in Creutzfeldt–Jakob’s disease, in
DLB, in frontotemporal and vascular dementias, and in PD with
dementia.
Previous findings in Parkinsonism. Previous studies in Parkin-
sonism were inconclusive, with both normal and decreased levels
in the same disorder, and did not allow drawing any conclusions
(Hall et al., 2012; for review, see Constantinescu et al., 2009). How-
ever, in vitro studies have shown that Aβ42 promotes accumulation
of alpha-synuclein making it interesting in a PD context (Masliah
et al., 2001).
More recent studies have found a correlation between Aβ42
and cognitive dysfunction in PD, with significantly lower CSF
Aβ42 and higher total tau protein levels in Parkinson’s disease
with dementia (PDD) compared with PD (Mollenhauer et al.,
2006). In addition, this pattern also distinguished AD from PD,
DLB, and MSA, although CSF Aβ42 was lower in DLB compared
with controls and PD (Zhang et al., 2008; Shi et al., 2011; Hall
et al., 2012). In a study from Norway, non-demented PD patients
with memory impairment had lower Aβ42 than those without
memory impairment (Alves et al., 2010). Significant associations
were found between cognitive performance and CSF levels of Aβ42
and Aβ42/total tau (Leverenz et al., 2011). Interestingly, in a rare
occurrence, the ratio fractalkine/Aβ42 correlated with PD severity
assessed by UPDRS-III (Shi et al., 2011).
DJ-1
Background. DJ-1 is a gene product associated with PD in both
familial and sporadic forms. Its exact function is not known but
it seems to play an important role in oxidative processes where it
probably acts as a protease, chaperon, or antioxidant (Choi et al.,
2006). Loss of DJ-1 function leads to neurodegeneration.
Previous findings in Parkinson’s disease. Previous studies have
found both higher (Waragai et al., 2006) and lower (Hong et al.,
2010) CSF DJ-1 levels in sporadic PD compared with non-PD con-
trols. DJ-1 will be investigated in the ongoing Parkinson Progres-
sion Markers Initiative study aiming to identify markers for disease
progression (Parkinson Progression Marker Initiative, 2011).
8-Hydroxydeoxyguanosine
Background. 8-Hydroxydeoxyguanosine (8-OHdG) is produced
when reactive oxygen radicals react with guanine residues in DNA.
When the oxidized DNA is repaired, 8-OHdG is excreted in the
blood and eventually in urine, where it can be measured. As such, it
has emerged as a marker of oxidation and mitochondrial dysfunc-
tion, not only in neurodegenerative disorders but also in cancer
research.
Previous findings in Parkinson’s disease. Sato et al. (2005) found
that the mean urinary 8-OHdG increased with the disease stage in
PD patients and another group found an association between hal-
lucinosis in PD and urinary 8-OHdG levels (Hirayama et al., 2011).
The CSF 8-OHdG levels were increased in non-demented PD
compared with controls (Gmitterova et al., 2009). 8-OHdG is one
of the parameters selected for assessment in the FS-ZONE study,
investigating the effect of pioglitazone, a potential antioxidant, in
early PD1. Increased 8-OHdG blood levels in PD were identified in
metabolomic studies as previously discussed in the metabolomics
section.
Urate
Background. In humans, uric acid is the major product of the
catabolism of the purine nucleosides adenosine and guanosine.
Purines are derived from dietary intake as well as from endogenous
metabolic processes (synthesis and cell turnover). The enzyme uri-
case which breaks down urate is absent in humans and apes, due
to mutations which occurred millions of years ago (Wu et al.,
1989). As a result, along with an extensive reabsorption of fil-
tered urate (>90%), humans have high serum urate levels (about
5 mg/dL in men), close to the maximum solubility. Levels above
the saturation limit (7 mg/dL) can result in hyperuricemia which
may be a cause of disease in humans. However, higher urate lev-
els may account for the greater longevity of humans, e.g., due to
lower cancer rates compared with shorted-lived mammals. Dur-
ing the evolution, urate has replaced ascorbate as the most potent
antioxidant in humans.
Previous findings in Parkinsonian disorders. There is a sub-
stantial amount of evidence showing a relationship between urate
and PD. Higher serum urate levels and higher dietary urate intake
are associated with lower risk for developing PD, and with slower
disease progression, better cognitive performance, and reduced
loss of striatal [123I] β-CIT uptake in patients already having
PD (Davis et al., 1996; Annanmaki et al., 2007; Annanmaki et al.,
2008; Ascherio et al., 2009). In a recent study, the ratio between
the immediate precursor of urate, xanthine, and homovanil-
lic acid, the major catabolite of dopamine, was different in PD
patients compared with controls and correlated with disease sever-
ity (Lewitt et al., 2011). The odds for having parkinsonism but
without signs of dopaminergic deficit on iodine-123-labeled 2-β-
carboxymethoxy-3-β-(4-iodophenyl) tropane ([123I]b-CIT) scan
were higher in subjects with higher urate levels (Schwarzschild
et al., 2011). In one small study serum urate levels were higher
in tauopathies compared with synucleinopathies (Constantinescu
et al., 2012). In MSA, higher serum urate was associated with
a lower rate of disease progression (Lee et al., 2011). In DLB,
serum urate levels were lower than in controls (Maetzler et al.,
2011). There are discrepancies in the reported data concerning the
importance of gender in this context. Some studies have found the
association with urate levels to be significant in men only, others
in both genders.
The title of a recent article reflects the encouraging data
centered on urate and its future perspectives: “Urate: a novel
1http://www.ninds.nih.gov/disorders/clinical_trials/-NCT01280123.htm
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biomarker of PD risk, diagnosis, and prognosis” (Cipriani et al.,
2010).
Peroxisome proliferator-activated receptor gamma coactivator-1
alpha
Background. Peroxisome proliferator-activated receptor gamma
coactivator-1 alpha (PGC-1α) is a key transcriptional co-regulator
involved in mitochondrial respiration, oxidative stress defense, and
adaptive thermogenesis (Puigserver and Spiegelman, 2003).
Previous findings in Parkinson’s disease. Reduced mRNA levels
of PGC-1α leading to mitochondrial dysfunction and neurode-
generation were found in Huntington’s disease models (Cui et al.,
2006), opening up for new therapeutic targets (McGill and Beal,
2006). The same phenomenon seems to occur in PD (Keeney et al.,
2009; Pacelli et al., 2011) and PGC-1α is under investigation in new
PD studies such as Pioglitazone in Early PD2 (FS-ZONE).
Combinations of CSF compounds
Hong et al. investigated PD patients, healthy controls, and AD
patients, and found that both DJ-1 and alpha-synuclein were
decreased in PD compared with the other groups. Alpha-synuclein
discriminated PD from controls with a sensitivity of 92% and
a specificity of 58%. For DJ-1 the sensitivity was 90% and the
specificity 70%. There was no association with disease sever-
ity. Combining alpha-synuclein with DJ-1 did not enhance the
performance of the test model. They emphasized that blood cont-
amination must be an exclusion criterion for sample analysis as it
influenced the results; likewise, age must be taken into considera-
tion as both DJ-1 and alpha-synuclein increased with age (Hong
et al., 2010).
Mollenhauer et al. investigated a large number of patients with
both synucleinopathies (PD, MSA, and DLB) and tauopathies
(PSP and AD) plus neurological controls, first in a training set
and afterward in a validation set. They found that a CSF alpha-
synuclein concentration of 1.6 pg/µL discriminated PD from non-
synucleinopathies with a 70% sensitivity and a 53% specificity. At
this cut-off, the positive predictive value for any synucleinopathy
was 91%. In the training set, a combination of alpha-synuclein,
tau protein, and age discriminated between synucleinopathies and
neurological controls and AD with an area under the curve (AUC)
of 0.908. In the validation cohort the AUC was 0.702 for dis-
criminating between synucleinopathies and a mixture of PSP,
normal pressure hydrocephalus, and neurological controls. Age,
not diagnosis, was the strongest factor affecting total tau pro-
tein levels. Only mean alpha-synuclein levels and not total tau, or
Aβ42 levels differentiated PD and MSA from neurological controls
(Mollenhauer et al., 2011).
Hall et al. assessed patients with synucleinopathies (PD, MSA,
DLB, and PDD), tauopathies (PSP, CBD, and AD) and healthy con-
trols using a panel of compounds: alpha-synuclein, total tau pro-
tein, hyperphosphorylated tau, Aβ42, and NFL. Alpha-synuclein
levels were decreased in synucleinopathies compared with con-
trols, PSP, and AD. NFL levels were substantially increased in APD.
2http://clinicaltrials.gov/ct2/show/NCT01280123
A receiver operating characteristics (ROC) analysis conducted to
determine the value of NFL to differentiate PD from APD resulted
in an AUC of 0.93. Total tau protein was decreased in PD compared
with controls, but increased in MSA and CBD compared with PD.
No significant change was seen in PSP. Aβ42 did not differ signif-
icantly between controls and PD, MSA, PSP, and CBD (Hall et al.,
2012).
Shi et al. examined patients with PD, MSA, AD, and healthy
controls. The fractalkine/Aβ1–42 ratio correlated positively with
PD severity (in cross-sectional studies) and with PD progres-
sion (in longitudinal studies). No other marker had shown this
association before. Fractalkine is important for the proper func-
tion of microglia. In addition, the Flt3 ligand, a cytokine which
acts as a neurotrophic and anti-apoptotic factor in CNS, could
alone differentiate between PD and MSA with a sensitivity of
99% and a specificity of 95%. Aβ1–42 levels were lower in PD
and MSA than in controls but higher than in AD. They could
not differentiate between PD and MSA. Total tau levels were also
lower in PD and MSA than in controls and AD. A combina-
tion of alpha-synuclein and phosphorylated tau/total tau could
also differentiate PD from MSA with a sensitivity of 90% and
a specificity of 71% but only when samples with blood conta-
mination were excluded. Alpha-synuclein was decreased in both
PD and especially in MSA compared with controls, presum-
ably reflecting aggregation or metabolic abnormalities (Shi et al.,
2011).
Bech et al. investigated a group of patients with Parkinsonian
disorders (PD, MSA, PSP, CBD, DLB, and PDD). They could con-
firm previous results concerning NFL. Thus, a ROC analysis of
NFL showed a sensitivity of 86% and a specificity of 81% with
a cut-off value of 284.7 ng/L for differentiating PD from atypical
parkinsonism. Aβ42 was low in DLB. Neither phosphorylated tau
nor total tau differed between the diagnostic groups (Bech et al.,
2012).
WHY ARE BIOMARKERS FOR PARKINSONIAN DISORDERS
NEEDED?
The ultimate reason for needing a biomarker is the fact that we
still do not have any disease-modifying treatment in movement
disorders. The lack of biomarkers is considered to be one of
the greatest limitations for developing such a treatment (Olanow
et al., 2008). Over years, there has been no shortage of thera-
peutic hypotheses or compounds to be tested; the list with failed
compounds is very long. The real problem has been the lack of a
reliable way to assess the underlying disease process and whether
an intervention could influence it and alter the course of the
disease (Ravina et al., 2003; Kieburtz and Ravina, 2007; Sherer,
2011).
It has been assessed that it takes 5 years of follow-up and 600
subjects participating in a randomized placebo-controlled trial in
order to detect a 20% slowing of functional decline. A biomarker
could dramatically reduce the resources needed for that (Hersch
and Rosas, 2011).
Considering the very nature of Parkinsonian disorders and
the limits it puts on the process of developing disease-modifying
therapies, biomarkers could be useful for solving many limiting
issues.
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THE DIFFERENTIAL DIAGNOSTIC ISSUE
Differential diagnosis can be difficult during early phases of
Parkinsonian disorders. What might look as PD in the beginning
could turn out to be PSP, MSA, or even CBD. What was initially
considered to be a synucleinopathy may end as a tauopathy. Ulti-
mately, the gold standard for diagnosis remains neuropathology.
Considering the substantial differences between these disorders,
mixing together patients with different diagnoses may lead to neg-
ative or inconclusive results in any therapeutic trial, even when
the therapy itself is efficient for one of these diagnoses. A bio-
marker pointing early toward the right diagnosis would increase
the probability of success.
A diagnostic biomarker would decrease the cost, time, and
effort it would take to secure a diagnosis. Currently, that is best
achieved through an assessment done by a movement disorders
specialist. A biomarker would simplify the diagnostic process.
Even when there is no doubt regarding diagnosis, an ideal bio-
marker could help stratify patients in subgroups which may show
different responses to a given therapy. That would make possible
a distinction between respondent and non-respondent diagnos-
tic subgroups, preventing the dismissal of a therapy when it does
not benefit the diagnostic group as a whole. Such a distinction
would also permit, within a given diagnostic group, to differenti-
ate and individualize treatment according to expected benefits or
risks, and expected disease progression and complications (Marek
et al., 2008). For example, young PD patients with an increased
risk for developing dyskinesias, once levodopa therapy is insti-
tuted, might need a different treatment approach compared with
patients with late disease onset and a low risk for dyskinesia but
high for dementia.
THE TIME OF DISEASE ONSET AND PROGRESSION ISSUE
To date, it is impossible to determine the exact date of onset in
Parkinsonian disorders. Once started, the disease is asymptomatic
for several years, followed by the emergence of non-specific, non-
diagnostic symptoms. Our “early” diagnosis based on the emer-
gence of motor symptoms probably describes an already advanced
disease process.
Thus, in PD, it has been calculated that up to 50–70% of
substantia nigra neurons are lost before symptomatic motor
abnormalities develop (Fearnley and Lees, 1991) and the pre-
motor period could be between 5 and 20 years long (Marek
et al., 2008). In one positron emission tomography study in
PD, a mean preclinical period of 5.6± 3.2 years was calculated
(Hilker et al., 2005). Results from the Honolulu-Asia Aging
Study do also place the onset of non-motor symptoms, such
as bowel movement abnormalities, 10 years or more before
the emergence of diagnostic motor symptoms (Abbott et al.,
2001).
The fact that the disease onset predates with years the time when
enough symptoms emerge for a diagnosis to be made, implies that
even efficacious therapies may show themselves powerless if given
when neurodegeneration has gone that far (Stern et al., 2012).
An ideal biomarker could detect the disease in presymptomatic
individuals or early in the disease course allowing an efficacious
disease-modifying therapy to act and “cure” or at least delay the
progression of disease.
For now, there is also no way of measuring disease progression.
The tools we have been using are clinical scales of which UPDRS
(Fahn et al., 1987) is the most widespread for PD and the Uni-
fied Multiple System Atrophy Rating Scale (UMSARS) for MSA.
However, these scales are no biomarkers and they are subject to
both investigator and patient bias and cannot be considered truly
objective; they are not reliable as their score can vary from hour
to hour due to medication, placebo, food intake, or a myriad of
other causes; they measure a combination of dopaminergic and
non-dopaminergic effects and not the disease process itself, nor
the direct effects of treatment over this process. Biomarkers are
needed to identify the development of disease, and monitor and
measure its progression.
THE EFFECTS OF THERAPY ISSUE
At the present time we do not have a way of assessing whether and
to which degree a therapeutic intervention has an impact on the
disease process: we cannot measure the effects of a therapy. The
clinical scales which we use today are subject to error, as discussed
before. In addition, as it was shown in the ELLDOPA study, clinical
measures such as UPDRS, and a more objective assessment, radio-
tracer imaging, moved in different directions after the therapeutic
intervention, levodopa treatment, leading to confusion in regard
to interpretation (Fahn et al., 2004). A further problem is that
radiotracer imaging, which, currently, is the best we have achieved
in regard to a PD biomarker, does only assess the integrity of the
dopaminergic pathways in the striatum and, maybe, although it is
controversial, the impact of therapy on these dopaminergic path-
ways (Agarwal and Stoessl, 2012). However, PD and also the APD,
are not only disorders of the dopaminergic system, but of several
other neurotransmitter systems, which these radiotracers do not
visualize.
In conclusion, biomarkers that can identify and monitor the
biochemical effect of drugs, also called “theragnostic markers,”
would greatly benefit the search for disease-modifying therapies as
well as could be employed usefully as surrogate markers in clinical
trials.
THE PATHO-ETIOLOGICAL ISSUE
The ultimate cause of Parkinsonian disorders remains unknown,
despite an abundance of theories. Most research has been directed
toward the elucidation of the etiology of PD. The vast majority
of PD cases are sporadic but approximately 5–10% are genetic. A
combination of both environmental and genetic factors is thought
to underlie the pathological processes. Considerable evidence
implicates oxidative stress in the degeneration of dopaminergic
neurons, through deficiencies in the major antioxidant systems,
and not only in the brain, but also in the periphery (Jenner, 1991;
Kikuchi et al., 2002). Closely linked to oxidative stress is mito-
chondrial dysfunction (Lin and Beal, 2006). Several hereditary
forms of Parkinsonism are caused by mutations in genes related to
mitochondria, such as PINK1 and PARK2 (Mortiboys et al., 2008;
Gegg et al., 2009). Environmental toxins such as rotenone and
paraquat, which can disturb mitochondrial function, are positively
associated with PD (Tanner et al., 2011). Alpha-synuclein, a major
component of Lewy bodies, inhibits the mitochondrial complex I
(Devi et al., 2008) and may cause impaired protein degradation
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and accumulation of abnormal proteins by disturbing the two
major systems which remove damaged proteins: (1) the ubiquitin–
proteasome pathway; and (2) the autophagy–lysosome pathway.
Transcription abnormalities caused by alpha-synuclein may dis-
turb metabolic pathways (Desplats et al., 2012). Abnormal inflam-
mation in the central nervous system, with activated microglia
and massive astrogliosis with increased levels of proinflamma-
tory cytokines (tumor necrosis factor – TNF-α, interleukins), has
been found in the CSF in PD; these proinflammatory compounds
may promote apoptosis and neuronal death (Hirsch et al., 2003,
2012) and have been suspected to contribute to the development
of PD (Czlonkowska et al., 2002) and PSP (Litvan, 2003). Sup-
porting this theory, it has been shown that use of non-steroidal
anti-inflammatory drugs (NSAIDs), particularly ibuprofen, was
associated with a lower risk for PD (Chen et al., 2003; Gao et al.,
2011). It is not known whether the glial activation is secondary
to neuronal death induced by other factors, or if it is the primary
cause to neuronal death (Schapira and Jenner, 2011).
The cause of MSA, a synucleinopathy, is not known. As for PD,
mitochondrial dysfunction and oxidative stress, genetic predispo-
sition, microglial activation, pesticides, and other environmental
toxins have been suggested as putative causes (Hanna et al., 1999;
Stefanova et al., 2007; Ahmed et al., 2012). Alpha-synuclein accu-
mulates in the oligodendrocytes but its source is not known,
neither why it leads to neuronal death. Presumably, disturbances
in the neurotrophic support offered by oligodendroglia to neurons
result in their degeneration (Ubhi et al., 2011).
As for the synucleinopathies, the ultimate causes of PSP and
CBD are not known. Again, a combination of environment and
genetics may start the pathological process resulting in accumu-
lation of hyperphosphorylated tau isoforms with four repeats,
oxidative stress, and neurodegeneration. Inflammation may also
be involved; using PET, microglia cell activation could be found
in the same regions where the PSP pathology is usually located
(Gerhard et al., 2006).
The bewildering complexity of the current etiological theories
may just confirm that we still do not understand the etiology of
Parkinsonism but it could also imply that treatment must also be
complex and oriented toward several potential targets at the same
time (Lang et al., 2012). The same may apply to biomarkers; it
could be preposterous to expect to find a single biomarker cov-
ering such a complex disease. A biomarker reflecting the etiology
of the disease might offer insights into the pathological mech-
anism itself, thereby opening the way for potentially successful
interventions.
CHALLENGES IN THE DEVELOPMENT OF BIOMARKERS FOR
PARKINSONIAN DISORDERS
Although several promising candidates exist, we still lack a reliable
biomarker for Parkinsonian disorders. Some of the obstacles on
the road to developing biomarkers will be discussed here.
DISEASE HETEROGENEITY
In Parkinsonian disorders in general and PD in particular, con-
sidering the heterogeneity of clinical presentations at onset, the
variability in clinical progression, the multitude of genetic vari-
ants and of possible etiologies, it is conceivable that no single
biomarker will ever be sufficient, but that several biomarkers will
need to be developed,covering biochemical, imaging,pathological,
and clinical aspects of the diseases (Marek et al., 2008).
DIAGNOSTIC UNCERTAINTIES
In Parkinsonian disorders, the diagnosis still remains clinical. Even
in the minority of PD cases which are identified through genetic
testing, the time for phenoconversion cannot be assessed in a pre-
cise and objective way. Clinical diagnostic criteria are susceptible to
subjective interpretation and may change over time, as it has hap-
pened to a certain degree with PSP. Ultimately, the diagnostic gold
standard remains neuropathological examination that can only be
ascertained post mortem. Obviously, this is a serious limitation
for all research regarding Parkinsonism.
SLOW RATE OF NEURODEGENERATION IN PD
The neurodegenerative process in PD develops insidiously over
many years and the degree of degeneration with associated CSF
alterations may be too low to be detected by the current labora-
tory methods. A consequence of that is the high susceptibility to
blood contamination which can have profound influence on CSF
analysis results.
AGE IMPACT
As most cases of Parkinsonian disorders occur in people aged
55 years and older, there is a high probability for concomitant
disorders including neurodegeneration related to other causes,
e.g., AD or cerebrovascular pathology. The impact of high age
per se and comorbidities associated with it has not been sufficiently
investigated and more needs to be done in that respect.
METHODOLOGICAL UNCERTAINTIES
It is not always clear which kind of measurement is most appro-
priate and which compounds are the best to explore, mak-
ing comparisons between studies sometimes difficult. Several of
the proteins associated with neurodegeneration are suspected
to be aggregation-prone and may exist in different forms, e.g.,
phosphorylated or unphosphorylated or have different post-
translational conformations. Should oligomers or polymers, the
mother substance or its metabolites be investigated?
BLOOD CONTAMINATION
While 80% of all proteins in the CSF derive from blood, only
20% are brain-derived (Reiber, 2001). The protein concentra-
tion in the blood is much higher than in the CSF, due to the
brain-blood barrier which isolates the CSF space. Proteins such
as alpha-synuclein are also present in the blood, in erythrocytes,
and in thrombocytes. Even minor blood contamination may pro-
foundly affect the results of CSF analysis. The integrity of the
blood-brain barrier is crucial for ascertaining that what is found
in the CSF reflects the brain environment and not a blood con-
tamination and therefore results from blood-contaminated CSF
should not be used. According to one American group, sam-
ples should not contain more than 10 erythrocytes per microliter
CSF (Caudle et al., 2010), or 500 erythrocytes per microliter
CSF according to an European recommendation (Teunissen et al.,
2009).
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FUTURE PERSPECTIVES
Some of the approaches which may benefit the quest for biomark-
ers in Parkinsonian disorders are proposed here.
STANDARDIZATION OF CSF RELATED PROCEDURES
Although there are some guidelines in place for the collection
and analysis of CSF, from both Europe and the US (Teunissen
et al., 2009; Caudle et al., 2010), there is no uniformly accepted
protocol making possible the standardization of CSF related pro-
cedures. The creation of such a protocol would increase the quality,
compatibility, and comparability of CSF related investigations.
INVESTIGATIONS IN UNMEDICATED PATIENTS
The impact of dopaminergic medications on potential markers for
Parkinsonian disorders is not sufficiently investigated and most
of the patients studied so far had been treated with one or more
antiparkinsonian medications at the time for LP. There is a need to
investigate CSF from unmedicated patients. Some ongoing studies,
such as the Parkinson Progression Marker Initiative will make that
possible in PD (Parkinson Progression Marker Initiative, 2011)
but similar studies are also needed in APD.
INVESTIGATIONS IN EARLY ATYPICAL PARKINSONISM
Although early PD has been and is being studied, there is a lack of
similar studies in early atypical Parkinsonism. This will have to be
addressed as understanding the early disease stages probably holds
the key to the development of useful biomarkers and efficacious
disease-modifying therapies.
INVESTIGATING PATTERNS OF POTENTIAL BIOMARKERS
Given the difficulties encountered when trying to identify single
compounds as biomarkers in Parkinsonism, there may be more
feasible to identify patterns of compounds serving as biomarkers.
Some illustrations of this concept are presented previously in this
review. The nature of these disorders may imply minute modifi-
cations in single CSF compounds, impossible to perceive, while
patterns of several such modifications might be more prone to
detection.
LONGITUDINAL STUDIES
Most of the available data concerning CSF biomarkers comes from
cross-sectional studies. Considering the chronic and insidious
nature of Parkinsonian disorders, there is a need for longitudi-
nal studies which alone could examine changes and patterns over
longer time periods.
GROUPING DIAGNOSES
Grouping diagnoses together, such as PD contra APD or synucle-
inopathies contra tauopathies, may facilitate developing biomark-
ers for these diagnostic groups. These biomarkers would be limited
and not able to distinguish between single diagnostic entities, but
they could be useful in particular circumstances.
INCREASED GENERALIZABILITY
All biomarker studies come from highly selected patient popula-
tions recruited via movement disorder clinics. In the future it will
be necessary to investigate a more heterogeneous Parkinsonian
population.
CONCLUSION: CLINICAL APPLICATIONS OF BIOMARKERS
Reliable biomarkers could be of great use in the develop-
ment of disease-modifying therapies and in the management
of Parkinsonian disorders, once a disease-modifying therapy is
developed, by:
(1) Indicating promising therapeutic approaches derived from a
patho-etiologic understanding of the disease;
(2) Translating results of drug tests in animals to human popula-
tions;
(3) Enriching study populations by identifying patients at risk for
a disease;
(4) Determining disease onset at an early stage, hopefully even
before the emergence of symptoms;
(5) Stratifying populations according to estimated disease pro-
gression, anticipated complications, expected therapy bene-
fits, and potential risks;
(6) Measuring the effects of a therapy on the disease process and
on disease progress;
(7) Determining when a therapeutic intervention can be discon-
tinued;
(8) Simplifying the drug regulatory process.
Considering their high positive potential in the management of
Parkinsonian disorders, the quest for biomarkers for these diseases
must continue unabated.
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